Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

    For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 M3jSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnTNlJKSzVyPUWuPFY3PiEQvF2= MV\TRW5ITVJ?
DOHH-2 NIPjW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTlwM{W2PFkh|ryP MU\TRW5ITVJ?
no-10 NFfKVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPhbHVOUUN3ME25MlkxOzlizszN MoL0V2FPT0WU
LS-513 NUTjc4kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfkTWM2OD1zMT6zOVQ4KM7:TR?= M4i5bHNCVkeHUh?=
ALL-PO MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj6TWM2OD1zMT63O|M1KM7:TR?= NH;ORW1USU6JRWK=
8-MG-BA NITlcWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF|LkGxNlMh|ryP NELxbndUSU6JRWK=
RPMI-8402 NVLjcINDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTF3Lki1N|ch|ryP M4jSenNCVkeHUh?=
EoL-1-cell NU\2Z|RvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF6LkW5OFgh|ryP NH3k[2JUSU6JRWK=
NALM-6 MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfNXXZ6UUN3ME2xPU4xOTZ5IN88US=> M{HrTnNCVkeHUh?=
DEL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf6TWM2OD1{MD6xOFcyKM7:TR?= MkDzV2FPT0WU
SR M1TIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn2N4hKSzVyPUKzMlY4OTVizszN Mmm0V2FPT0WU
697 NUjwdmpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[3OXNKSzVyPUK2MlYyPTVizszN NFS1cIJUSU6JRWK=
COLO-829 NXr6eXBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLuTWM2OD1{Nj64OFg{KM7:TR?= M1XPN3NCVkeHUh?=
EVSA-T MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSweWozUUN3ME2yO{42PTZzIN88US=> MmjTV2FPT0WU
ATN-1 NGToNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTNzLkKzNlkh|ryP MkLUV2FPT0WU
L-363 M{K5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXKTWM2OD1|MT63OFYyKM7:TR?= MnjhV2FPT0WU
LAMA-84 NHjWd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LhUGlEPTB;M{KuOVIyOSEQvF2= NX7rZXhDW0GQR1XS
NOS-1 M1nySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTN2LkK5OVYh|ryP NFzS[ItUSU6JRWK=
BB30-HNC M3zoSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\ISnRlUUN3ME2zOE4{OzB4IN88US=> M{nIZ3NCVkeHUh?=
BC-1 NVf1UnQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3iTWM2OD1|Nz65O|Q3KM7:TR?= MlzOV2FPT0WU
IST-SL2 Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTN6LkKyOEDPxE1? MWHTRW5ITVJ?
D-392MG NHm0NWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3UOmVKSzVyPUSwMlIzOTVizszN NE[2Nm9USU6JRWK=
no-11 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XYSWlEPTB;NECuOVUzOSEQvF2= NXHn[I5EW0GQR1XS
LC4-1 MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3MTWM2OD12MD64O|E3KM7:TR?= MXjTRW5ITVJ?
A388 M{TNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTR{LkW4OFgh|ryP MmroV2FPT0WU
NTERA-S-cl-D1 MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITydY5KSzVyPUSyMlcxPzRizszN NXTNdFhMW0GQR1XS
CESS M4XuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTR2LkKyN|Ih|ryP Mn7jV2FPT0WU
RS4-11 M3SxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LZUGlEPTB;NEmuNFk{QCEQvF2= NXvnOFh2W0GQR1XS
MS-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTVyLkmzOVEh|ryP NF;zPHRUSU6JRWK=
CTV-1 NEDyRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTVzLkC3OEDPxE1? NE\PSFlUSU6JRWK=
D-502MG MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe2bpFwUUN3ME21NU43OjdzIN88US=> MVPTRW5ITVJ?
ML-2 M1jtcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTV{LkmxPVUh|ryP MUHTRW5ITVJ?
SK-NEP-1 NFfUVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTV|LkO5NlMh|ryP MlrUV2FPT0WU
LOXIMVI MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO3e4tKSzVyPUWzMlU5QDRizszN M2HhcnNCVkeHUh?=
DJM-1 M3nQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXtcWZKSzVyPUW2MlM{QTFizszN MlrCV2FPT0WU
GI-1 Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzsSlJHUUN3ME21Ok43OTR7IN88US=> M{HBRnNCVkeHUh?=
IST-MES1 MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3JSlJKSzVyPU[wMlU1QTNizszN NWPrbJR7W0GQR1XS
MV-4-11 NFnrWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTlTWM2OD14MD62OVM5KM7:TR?= NYrvR4UxW0GQR1XS
OVCAR-4 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW5WIJvUUN3ME22N{42PjV5IN88US=> NFvmdZZUSU6JRWK=
KE-37 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37DOGlEPTB;Nk[uNlY3QCEQvF2= NIK4V5dUSU6JRWK=
D-542MG MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TVc2lEPTB;NkiuOFE{PSEQvF2= M3HUOHNCVkeHUh?=
MHH-PREB-1 M3HEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDwTWM2OD15Mj64OFQyKM7:TR?= MmDVV2FPT0WU
MRK-nu-1 NEfSOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfHUlVKSzVyPUezMlQ4ODVizszN MnTXV2FPT0WU
D-247MG Ml74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjVXVdxUUN3ME23N{42PDR{IN88US=> NVvWdnZmW0GQR1XS
OCI-AML2 Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTd4LkmzOlkh|ryP MUDTRW5ITVJ?
LP-1 NGLwbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\UUolSUUN3ME24Nk45PzNzIN88US=> NH62WY9USU6JRWK=
HCC1599 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTh2LkK4N|ch|ryP M4HFO3NCVkeHUh?=
KARPAS-45 NUTYUnBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf0OmpSUUN3ME24OE43QTl{IN88US=> MXfTRW5ITVJ?
BE-13 MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2flPGlEPTB;OUmuNFQ4PyEQvF2= NELPelJUSU6JRWK=
GCIY NH3mWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\sXmlEPTB;OUmuNFk2PCEQvF2= NWTvOphjW0GQR1XS
BV-173 NX20NFc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFyMD6zNlUh|ryP MXXTRW5ITVJ?
LB2518-MEL M4rVZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX5dGJKSzVyPUGwNE44QDlizszN NVHzdW95W0GQR1XS
KS-1 NHzwc3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUOz[2FzUUN3ME2xNFEvPjN7IN88US=> MVPTRW5ITVJ?
MOLT-16 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PtbmlEPTB;MUC0Mlk5PiEQvF2= MmXlV2FPT0WU
NCI-H1770 NYTmeVYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTNcmdPUUN3ME2xNFgvPzh2IN88US=> NFX4bVFUSU6JRWK=
NCI-H82 NH;qVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFzMD65O|Yh|ryP NH3HNJBUSU6JRWK=
NCCIT NX7jR4xTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HQS2lEPTB;MUGyMlUzQSEQvF2= MoXCV2FPT0WU
KALS-1 NXHne45sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\ENmlEPTB;MUG1Mlk1OSEQvF2= NHTwS3NUSU6JRWK=
LB2241-RCC Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu5VHBKSzVyPUGxOk43PzlizszN MlviV2FPT0WU
HH NIL2UIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\6TWM2OD1zMUeuN|k2KM7:TR?= MYHTRW5ITVJ?
HD-MY-Z MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrPU5hpUUN3ME2xNVgvPDh6IN88US=> M4jGdXNCVkeHUh?=
EB-3 NHfuR4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL5N5VyUUN3ME2xNlMvODl2IN88US=> MmraV2FPT0WU
BL-70 NUTWSWV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfYTWM2OD1zMkOuNVI4KM7:TR?= MnjYV2FPT0WU
K-562 NGi3Z3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LtUWlEPTB;MUK2MlI1PSEQvF2= NIW2Z4tUSU6JRWK=
HT-144 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfTbItKSzVyPUGzN{4yPjRizszN NVHjSVY4W0GQR1XS
PF-382 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnZOHJKSzVyPUGzOE4{PjFizszN NXzX[FRCW0GQR1XS
RPMI-8226 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\rcWlEPTB;MUO1MlA1PSEQvF2= NY\yeHozW0GQR1XS
NCI-H1355 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HPTGlEPTB;MUO1MlU5PyEQvF2= NHSzbnBUSU6JRWK=
LXF-289 MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HndWlEPTB;MUO5Mlc5OSEQvF2= Mn3PV2FPT0WU
NCI-H69 M2PPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF2Mj65N|Ih|ryP M3PCTnNCVkeHUh?=
SK-MEL-1 MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHaS3VKSzVyPUG0O{4yOyEQvF2= MorCV2FPT0WU
KARPAS-299 NXnyT2RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF2OT6xNkDPxE1? NH7jdXZUSU6JRWK=
GB-1 MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml2xTWM2OD1zNEmuN|IzKM7:TR?= MV3TRW5ITVJ?
CMK MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XxfGlEPTB;MUS5MlUyPSEQvF2= M4Lq[XNCVkeHUh?=
MPP-89 M{f6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jrXWlEPTB;MUW2MlA{PSEQvF2= NEfCRoJUSU6JRWK=
KU812 NYfrTGRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr3U2tqUUN3ME2xOlEvQTB{IN88US=> MUDTRW5ITVJ?
REH NGTCN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vweGlEPTB;MU[yMlEzPSEQvF2= MU\TRW5ITVJ?
NEC8 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrib|ZKSzVyPUG2OU4xOjZizszN NVTOTFU6W0GQR1XS
KP-N-YS M4Tl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjiTWM2OD1zNkiuN|k2KM7:TR?= MUXTRW5ITVJ?
Ramos-2G6-4C10 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfjN4xKSzVyPUG2PU46OTVizszN MVzTRW5ITVJ?
Becker NYrFd|lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\hTWM2OD1zN{SuNVgh|ryP MnTqV2FPT0WU
LB647-SCLC NX\wcYtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTF5NT64OFUh|ryP NUHZ[pI2W0GQR1XS
LU-139 NILDXWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTF5OD6wNVkh|ryP MV3TRW5ITVJ?
QIMR-WIL MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XE[mlEPTB;MUe5MlY1PiEQvF2= MoLKV2FPT0WU
NCI-H1395 M1SwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn75TWM2OD1zN{muPVk3KM7:TR?= NULzU4VtW0GQR1XS
NOMO-1 NUTPVYVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X6UWlEPTB;MUiyMlg2KM7:TR?= NHexUFJUSU6JRWK=
GI-ME-N MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTF6Nz65Olkh|ryP M{nMbHNCVkeHUh?=
KMS-12-PE NUO1S5MzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M333[2lEPTB;MUi5MlI4OyEQvF2= MnPiV2FPT0WU
Daudi M4rVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF7MT6xNlgh|ryP M3v5S3NCVkeHUh?=
LB996-RCC M{H3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\zfGlEPTB;MUmxMlY6QSEQvF2= MnHKV2FPT0WU
NCI-H2107 M1;Z[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX2RVZKSzVyPUG5N{44OzlizszN NYPU[FBnW0GQR1XS
SK-PN-DW NHTzWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTySVAzUUN3ME2xPVQvPzF7IN88US=> MX;TRW5ITVJ?
MC-CAR MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGmzcnhKSzVyPUKwNk4zPTNizszN MnnsV2FPT0WU
SNB75 NFG1XYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJ{MT65OEDPxE1? NV\CPJRDW0GQR1XS
ES4 NXO4fppLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJ{Mz63PFMh|ryP NHLmc21USU6JRWK=
KARPAS-422 Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHETWM2OD1{MkiuN|UzKM7:TR?= NE\rSo9USU6JRWK=
NCI-H1648 M3XlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjVTWM2OD1{MkmuOFg6KM7:TR?= NUD6S2gyW0GQR1XS
ES6 NGLlXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW1foxHUUN3ME2yN|kvPDNizszN NInWPGJUSU6JRWK=
KNS-81-FD NXuz[JB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJ2MT6xPVch|ryP MnrTV2FPT0WU
JAR Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK4cHVQUUN3ME2yOVYvOjJ3IN88US=> NEnrOZRUSU6JRWK=
NB1 NY\ScHZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrTPXdSUUN3ME2yOlAvPTF4IN88US=> MoXzV2FPT0WU
D-336MG NGf2V5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJ4MD62PVgh|ryP M4nJZnNCVkeHUh?=
BC-3 NFfCboxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr1TWM2OD1{NkWuNVc5KM7:TR?= MlLoV2FPT0WU
HCC2218 M2rVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq2[Y9LUUN3ME2yOlYvPDF3IN88US=> M{PwW3NCVkeHUh?=
TE-9 M1rRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HGeWlEPTB;Mk[2MlYzPyEQvF2= NUC0Z3llW0GQR1XS
LB1047-RCC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTJ4Nj63OVMh|ryP M33QOHNCVkeHUh?=
CTB-1 NGK5XmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJ4OT65O|Mh|ryP NXPm[3JVW0GQR1XS
NB7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITPS5dKSzVyPUK3NUDPxE1? NGXzblJUSU6JRWK=
ST486 NYnu[HN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\wcGJKSzVyPUK3O{41OTJizszN M1u3XnNCVkeHUh?=
HCC1187 NF\DV4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jsbWlEPTB;MkiyMlgyOSEQvF2= MX;TRW5ITVJ?
NCI-SNU-16 NIrIenJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXpTWM2OD1{OESuNlQ5KM7:TR?= NHyyT5RUSU6JRWK=
COR-L279 MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTJ7MT61PFQh|ryP NHrrfG5USU6JRWK=
ES8 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJ7ND6xPFIh|ryP M4q0T3NCVkeHUh?=
U-698-M M2HMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUS2TWRDUUN3ME2yPVgvOjR|IN88US=> M4KyN3NCVkeHUh?=
HEL MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTNyOT6xOFkh|ryP MkLUV2FPT0WU
KINGS-1 NF7QVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTFZYVxUUN3ME2zNVAvPjd2IN88US=> NUDzcGRxW0GQR1XS
KY821 NFzlTWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\ROmlEPTB;M{O2MlU6PSEQvF2= NIHjTXRUSU6JRWK=
MZ1-PC NV33fFZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\aU|dKSzVyPUO0OU43OThizszN MlvtV2FPT0WU
LS-411N NU\kellnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTmeolKSzVyPUO1OE43PiEQvF2= NUHRcJNZW0GQR1XS
SIG-M5 NV;FOng1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TO[mlEPTB;M{W5Mlc5OiEQvF2= MkfmV2FPT0WU
HT MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrKcHhKSzVyPUO2O{44OTFizszN NXvubIVpW0GQR1XS
HC-1 NVHUTHF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTN4Nz63PFch|ryP M4jJPXNCVkeHUh?=
NCI-H1694 MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HkRWlEPTB;M{eyMlk{PCEQvF2= M2S0d3NCVkeHUh?=
BB65-RCC MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELXR2NKSzVyPUO3Ok4zPDVizszN M1qyWXNCVkeHUh?=
HAL-01 NV6zV2hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLJTWM2OD1|N{muPFM5KM7:TR?= M4ryU3NCVkeHUh?=
ARH-77 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnwbIwxUUN3ME2zPVQvODB6IN88US=> MkTDV2FPT0WU
MZ7-mel M{L3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO0UZpiUUN3ME2zPVcvOjN|IN88US=> M3fkW3NCVkeHUh?=
SIMA MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPNVmlKSzVyPUSwN{46OzNizszN NWizc2pUW0GQR1XS
DG-75 NHTabFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TsN2lEPTB;NEG1MlY6QCEQvF2= MWHTRW5ITVJ?
HUTU-80 M2fVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELaeGhKSzVyPUSxPU4yQDVizszN M2D5WnNCVkeHUh?=
KNS-42 NHT2Rm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTR{NT64NVUh|ryP M{jae3NCVkeHUh?=
SH-4 NWfsWldQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTR{Nz61OlUh|ryP M3[3OXNCVkeHUh?=
L-540 M4DuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPmfZNKSzVyPUSzNU4xOzFizszN NGfwdXZUSU6JRWK=
NB10 NIDDWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rqO2lEPTB;NESxMlI{PCEQvF2= Ml3QV2FPT0WU
ES1 MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3GzSWlEPTB;NEWyMlc2OyEQvF2= M4fsRXNCVkeHUh?=
KMOE-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTR3Nj63NVEh|ryP M{\1O3NCVkeHUh?=
MC116 M2Lv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfvbHBnUUN3ME20OVgvOTF4IN88US=> MUPTRW5ITVJ?
RCC10RGB MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTR4MD6wNFUh|ryP NU\jUlhVW0GQR1XS
RL95-2 M1PKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXsTWM2OD12NkCuNlM4KM7:TR?= NHfNTJVUSU6JRWK=
Raji M2jZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTTdVQ5UUN3ME20OlgvOTR|IN88US=> Ml7LV2FPT0WU
CAS-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlexTWM2OD12N{KuNFc{KM7:TR?= NH3RTVlUSU6JRWK=
Calu-6 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDJTWM2OD12N{WuNlY2KM7:TR?= NF3udYZUSU6JRWK=
KG-1 NUi2TWkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTR5OD60OEDPxE1? NXLyW2N1W0GQR1XS
LB771-HNC M2nNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;HPVFKSzVyPUS4Nk4zOzJizszN M3fyNnNCVkeHUh?=
ACN NV3Qc2hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTR7Mz61PVkh|ryP NUnINFB7W0GQR1XS
KM12 MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LwVmlEPTB;NEm2MlU5QSEQvF2= NXrkSIc5W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO slightly soluble or insoluble
In vivo Add solvents individually and in order:
10% DMSO+30% PEG 300+5% Tween 80+ddH2O
1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID